TEAD1 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9; X = 1 bp insertion, 2 bp insertion; Frameshift = 99.74%.
Images
Key facts
- Cell type
- A549
- Species or organism
- Human
- Tissue
- Lung
- Knockout validation
- Next Generation Sequencing, Western blot
- Mutation description
- Knockout achieved by CRISPR/Cas9; X = 1 bp insertion, 2 bp insertion; Frameshift = 99.74%
Alternative names
AA, Atrophia areata peripapillary chorioretinal degeneration, NTEF-1, Protein GT-IIC, REF-1, SV40 transcriptional enhancer factor, TCF-13, TEA domain family member, TEA domain family member 1, TEA domain family member 1 (SV40 transcriptional enhancer factor), TEAD 1 protein, TEAD1_HUMAN, TEF1, Transcription factor 13, Transcription factor 13 (SV40 transcriptional enhancer factor), Transcriptional enhancer factor 1, Transcriptional enhancer factor TEF-1, tef-1
What's included?
Recommended products
TEAD1 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9; X = 1 bp insertion, 2 bp insertion; Frameshift = 99.74%.
Key facts
- Cell type
- A549
- Species or organism
- Human
- Tissue
- Lung
- Knockout validation
- Next Generation Sequencing, Western blot
- Mutation description
- Knockout achieved by CRISPR/Cas9; X = 1 bp insertion, 2 bp insertion; Frameshift = 99.74%
- Disease
- Carcinoma
- Concentration
Properties
- Gene name
- TEAD1
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Next Generation Sequencing, Western blot
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 1 US: 1
- Adherent/suspension
- Adherent
- Gender
- Male
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3 product images
Western blot - Human TEAD1 knockout A549 cell lysate (ab261718)
Lane 1: Wild-type A549 (Human lung carcinoma cell line) whole cell lysate
Lane 2: TEAD1 knockout A549 (Human lung carcinoma cell line) whole cell lysate
Lanes 1 - 2: Merged signal (red and green). Green - Anti-TEF1/TEAD-1 antibody [EPR3968(2)] ab133535 observed at 50 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 (Mouse anti-GAPDH antibody [6C5]) observed at 37kDa.
Anti-TEF1/TEAD-1 antibody [EPR3968(2)] ab133535 was shown to react with TEF1/TEAD-1 in wild-type A549 cells in western blot with loss of signal observed in TEAD1 knockout cell line Human TEAD1 knockout A549 cell line ab261901 (knockout cell lysate Human GYS1 (Glycogen synthase 1) knockout HEK-293 cell lysate ab263917). Wild-type and TEAD1 knockout A549 cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% milk in TBS-T (0.1% Tween®) before incubation with Anti-TEF1/TEAD-1 antibody [EPR3968(2)] ab133535 and Anti-GAPDH antibody [6C5] - Loading Control ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.All lanes: Western blot - Anti-TEF1/TEAD-1 antibody [EPR3968(2)] (Anti-TEF1/TEAD-1 antibody [EPR3968(2)] ab133535) at 1/1000 dilution
Lane 1: Wild-type A549 (Human lung carcinoma cell line) whole cell lysate at 20 µg
Lane 2: TEAD1 knockout A549 (Human lung carcinoma cell line) whole cell lysate at 20 µg
Lane 2: Western blot - Human TEAD1 knockout A549 cell line (Human TEAD1 knockout A549 cell line ab261901)
Performed under reducing conditions.
Predicted band size: 48 kDa
Observed band size: 50 kDa
Western blot - Human TEAD1 knockout A549 cell lysate (ab261718)
Lane 1: Wild-type A549 (Human lung carcinoma cell line) whole cell lysate
Lane 2: TEAD1 knockout A549 (Human lung carcinoma cell line) whole cell lysate
Lanes 1 - 2: Merged signal (red and green). Green - Anti-TEF1/TEAD-1 antibody [EPR3967(2)] ab133533 observed at 50 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 (Mouse anti-GAPDH antibody [6C5]) observed at 37kDa.
Anti-TEF1/TEAD-1 antibody [EPR3967(2)] ab133533 was shown to react with TEF1/TEAD-1 in wild-type A549 cells in western blot with loss of signal observed in TEAD1 knockout cell line Human TEAD1 knockout A549 cell line ab261901 (knockout cell lysate Human GYS1 (Glycogen synthase 1) knockout HEK-293 cell lysate ab263917). Wild-type and TEAD1 knockout A549 cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% milk in TBS-T (0.1% Tween®) before incubation with Anti-TEF1/TEAD-1 antibody [EPR3967(2)] ab133533 and Anti-GAPDH antibody [6C5] - Loading Control ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.All lanes: Western blot - Anti-TEF1/TEAD-1 antibody [EPR3967(2)] (Anti-TEF1/TEAD-1 antibody [EPR3967(2)] ab133533) at 1/1000 dilution
Lane 1: Wild-type A549 cell lysate at 20 µg
Lane 2: TEAD1 knockout A549 (Human lung carcinoma cell line) whole cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 48 kDa
Observed band size: 50 kDa
Next Generation Sequencing - Human TEAD1 knockout A549 cell lysate (ab261718)
Knockout achieved by CRISPR/Cas9; X = 1 bp insertion, 2 bp insertion; Frameshift = 99.74%
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com